Ratiometric drug delivery using non-liposomal nanocarriers as an approach to increase efficacy and safety of combination chemotherapy - 15/12/17
pages | 12 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Abstract |
The observation that different drug ratios of the same drug combination can lead to synergistic or antagonistic effects when tested against the same cancer cell line in vitro gave rise to a new trend, the ratiometric delivery. This strategy consists of co-encapsulating a specific synergistic ratio of a drug combination into a nanocarrier so that synergism observed in vitro will be faithfully translated to in vivo, optimizing combination therapy. In this review we focus on how to quantify synergism in vitro, followed by how this affected the evolution of nanocarriers culminating in the ratiometric delivery, and finally we summarize the results of the non-liposomal formulations that were built upon this concept.
Le texte complet de cet article est disponible en PDF.Keywords : Ratiometric delivery, Drug combination, Cancer, Solid polymer–lipid hybrid nanoparticles, Polymeric nanoparticles, Solid lipid nanoparticles, Telodendrimer micelles, Macromolecular carrier
Plan
Vol 96
P. 584-595 - décembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?